SNDX
Syndax Pharmaceuticals Inc
17.60$
-3.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | +94.6% | +72.8% | -28.0% | +0.0% | +0.0% | +9,109.6% | -9.4% | -100.0% | – | +627.8% | |
| – | – | – | – | – | +97.4% | +53.5% | -100.0% | – | – | – | -0.4% | -97.4% | +6,783.3% | +743.8% | |
| – | – | – | – | – | +94.6% | +72.8% | -28.0% | +0.0% | +0.0% | +9,109.6% | -100.3% | – | – | +623.6% | |
| – | -13.9% | -38.8% | +217.2% | -6.2% | +231.6% | +52.2% | +24.7% | -28.5% | +17.3% | +75.0% | +34.3% | +37.6% | +48.2% | +7.1% | |
| – | – | +53.5% | +108.0% | +3.9% | +14.9% | +19.1% | +9.0% | -7.1% | +40.1% | +12.2% | +31.8% | +101.2% | +80.6% | +48.6% | |
| – | -8.8% | -1.9% | +148.9% | -0.9% | +112.8% | +42.4% | +20.8% | -23.7% | +23.5% | +55.6% | +33.7% | +51.5% | +57.7% | +20.9% | |
| – | – | – | – | – | – | – | – | – | – | – | -678.8% | – | – | – | |
| – | -100.0% | – | – | – | -39.3% | +48.6% | +36.7% | -19.1% | +50.0% | -19.4% | +65.2% | -93.4% | +2,269.7% | +585.4% | |
| – | – | – | – | – | – | – | – | – | – | – | -699.1% | – | – | – | |
| – | – | +110.2% | -158.0% | – | -105.8% | – | – | -104.8% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -676.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -677.7% | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.